We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
cancer: Archive
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
NEONegative Net Change EXASNegative Net Change NVTANegative Net Change NTRANegative Net Change GHNegative Net Change
biotechs cancer genetics genomics medical
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
EXASNegative Net Change ADPTNegative Net Change NVTANegative Net Change NTRANegative Net Change GHNegative Net Change
cancer coronavirus genetics genomics
Bear of the Day: Guardant Health (GH)
by Kevin Cook
Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise
GHNegative Net Change EXASNegative Net Change
cancer genetics genomics medical
Bear of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing
CRSPNegative Net Change EDITNegative Net Change ARKKNegative Net Change NTLANegative Net Change ARKGNegative Net Change
biofuels cancer genetics genomics medical
Bull of the Day: Hologic (HOLX)
by Kevin Cook
This leader in women's health diagnostics is ramping high double-digit growth on COVID testing
QDELPositive Net Change HOLXPositive Net Change
cancer coronavirus medical
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
GILDNegative Net Change IBBNegative Net Change CNCRNegative Net Change BBHNegative Net Change FBTNegative Net Change PTHNegative Net Change IHFNegative Net Change IHENegative Net Change XPHNegative Net Change SBIONegative Net Change XHSNegative Net Change PBENegative Net Change IDNANegative Net Change
biotechs cancer etfs